Once-daily diabetes drug approved FDA approved 10 mg dapagliflozin and 5 mg saxagliptin (Qtern, AstraZeneca), to treat type 2 diabetes. New diabetes medications help address linked diseases Experts share updates on new diabetes medications, and provide an overview of what’s coming. Watch list 2017: Top therapeutic areas January 03, 2017 By Mari Edlin Find out about the latest treatment and drug pipeline developments New diabetes combo drug available soon December 19, 2016 By Christine Blank A new combination drug for type 2 diabetes will available in the US in the coming months. New drug indication could net more than $1 billion December 05, 2016 By Christine Blank FDA’s approval of a new indication for empagliflozin (Jardiance, Eli Lilly and Boehringer Ingelheim) could net the pharmaceutical manufacturers more than $1 billion. Invokamet extended-release approved for diabetes September 26, 2016 By Christine Blank FDA recently approved an expanded use for Invokamet (Janssen): Invokamet XR, an extended-release combination drug to treat type 2 diabetes. The original Invokamet was approved by FDA in 2014. New diabetes drug up against leading brands July 29, 2016 By Christine Blank FDA approved lixisenatide (Adlyxin, Sanofi-Aventis), a once-daily mealtime GLP-1 receptor agonist injection for type 2 diabetes, which will compete against the once-weekly pen dulaglutide (Trulicity, Eli Lilly) and the injectable liraglutide (Victoza, Novo Nordisk). FDA issues a new warning about popular diabetes drug June 10, 2016 By Christine Blank FDA approves a new indication, then issues strengthened warning about possible effects. New diabetes drug enters competitive market June 01, 2016 By Christine Blank In a major new entry in the diabetes market, FDA just approved linagliptin and metformin hydrochloride extended-release tablets (Jentadueto XR, Boehringer Ingelheim and Eli Lilly and Company) to treat type 2 diabetes. Pharma company keeps pace with rise of diabetes May 31, 2016 By Erin Bastick Novo Nordisk’s new diabetes drug production facility in Clayton, N.C., will ensure production capacity for these drugs in the United States for the decade ahead.